Welcome to our dedicated page for Edgewise Therapeutics SEC filings (Ticker: EWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edgewise Therapeutics, Inc. filings document a late-stage clinical biopharmaceutical company developing treatments for severe muscle diseases, including programs for muscular dystrophies and serious cardiac conditions. Form 8-K reports furnish quarterly and annual financial results, Regulation FD clinical-program disclosures, and material governance events.
The company’s proxy materials describe board structure, director elections, executive compensation, equity-award information, stockholder voting matters, and governance practices. Other disclosed matters include officer appointments, director appointments, compensatory arrangements, exhibits to earnings releases, and operating context for a development-stage drug pipeline.
Edgewise Therapeutics (EWTX) director Badreddin Edris received a stock option grant for 30,000 shares of common stock on June 16, 2025. The options were granted with an exercise price of $14.68 per share.
Key terms of the stock option grant:
- Exercise price: $14.68 per share
- Vesting schedule: 100% vesting on the earlier of June 16, 2026, or the day before the 2026 annual stockholder meeting
- Expiration date: June 16, 2035
- Ownership form: Direct
The Form 4 was filed by attorney-in-fact John R. Moore on behalf of Badreddin Edris on June 18, 2025, within the required two-business-day filing window following the transaction.
Edgewise Therapeutics director Jonathan C. Fox received a stock option grant on June 16, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:
- Grant of 30,000 stock options to purchase common stock
- Exercise price set at $14.68 per share
- Options will vest fully on the earlier of June 16, 2026 or the day before the 2026 annual stockholder meeting
- Options expire on June 16, 2035
This grant represents a standard annual director compensation award. The filing was signed by John R. Moore as attorney-in-fact for Fox on June 18, 2025. The reporting person maintains direct ownership of these derivative securities.
Edgewise Therapeutics Director Arlene Morris received a stock option grant on June 16, 2025, representing a significant insider transaction. The key details of this Form 4 filing include:
- Granted 30,000 stock options to purchase common stock
- Exercise price set at $14.68 per share
- Options will vest fully on the earlier of June 16, 2026 or the day before the 2026 annual stockholder meeting
- Options expire on June 16, 2035
This grant appears to be part of the company's director compensation program. The one-year cliff vesting schedule aligns with typical board member equity compensation structures. The filing was completed by Attorney-in-Fact John R. Moore on June 18, 2025.
Edgewise Therapeutics (EWTX) reported a Form 4 filing disclosing insider trading activity by Director Jonathan D. Root. On June 16, 2025, Root was granted 30,000 stock options with the following key terms:
- Exercise price: $14.68 per share
- Vesting schedule: 100% vesting on the earlier of June 16, 2026, or the day before the 2026 annual stockholder meeting
- Expiration date: June 16, 2035
- Ownership type: Direct
The stock options represent the right to purchase 30,000 shares of Edgewise Therapeutics common stock. The transaction was executed under standard compensation arrangements for directors, with zero cost basis for the options grant. The filing was completed by John R. Moore as attorney-in-fact for Jonathan Root on June 18, 2025.
Peter A. Thompson, who serves as both Director and 10% Owner of Edgewise Therapeutics (EWTX), received a stock option grant on June 16, 2025. The derivative securities transaction details include:
- Grant of 30,000 stock options to purchase common stock
- Exercise price set at $14.68 per share
- Options will vest 100% on the earlier of:
- June 16, 2026, or
- The business day before the 2026 annual stockholder meeting
- Options expire on June 16, 2035
The transaction was reported via Form 4 filing, signed by John R. Moore as attorney-in-fact for Peter Thompson on June 18, 2025. This equity compensation grant aligns with standard director compensation practices and represents a long-term incentive structure with a one-year cliff vesting period.